Symbols / DRUG Stock $71.46 -0.36% Bright Minds Biosciences Inc.

Healthcare • Biotechnology • United States • NCM
DRUG (Stock) Chart
About

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 699.39M
Enterprise Value 610.45M Income -19.84M Sales —
Book/sh 8.25 Cash/sh 9.10 Dividend Yield —
Payout 0.00% Employees 26 IPO —
P/E — Forward P/E -10.95 PEG —
P/S — P/B 8.67 P/C —
EV/EBITDA — EV/Sales — Quick Ratio 56.59
Current Ratio 57.37 Debt/Eq 0.12 LT Debt/Eq —
EPS (ttm) -1.99 EPS next Y -6.53 EPS Growth —
Revenue Growth — Earnings 2026-05-15 ROA -15.72%
ROE -26.98% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 9.79M
Shs Float 6.61M Short Float 7.03% Short Ratio 4.98
Short Interest — 52W High 123.75 52W Low 23.18
Beta -0.11 Avg Volume 151.21K Volume 188.47K
Target Price $165.37 Recom Strong_buy Prev Close $71.72
Price $71.46 Change -0.36%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$165.37
Mean price target
2. Current target
$71.46
Latest analyst target
3. DCF / Fair value
$-14.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$71.46
Low
$142.51
High
$188.24
Mean
$165.37

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-30 reit BTIG Buy → Buy $147
2026-03-04 main HC Wainwright & Co. Buy → Buy $145
2026-02-17 main BTIG Buy → Buy $147
2026-01-07 main BTIG Buy → Buy $147
2026-01-06 main BTIG Buy → Buy $147
2026-01-02 main Chardan Capital Buy → Buy $80
2025-12-30 reit HC Wainwright & Co. Buy → Buy $115
2025-09-15 reit HC Wainwright & Co. Buy → Buy $85
2025-09-08 init BTIG — → Buy $72
2025-08-19 reit HC Wainwright & Co. Buy → Buy $85
2025-05-21 main Chardan Capital Buy → Buy $80
2025-05-13 init TD Cowen — → Buy —
2025-05-07 init Chardan Capital — → Buy $80
2025-02-19 reit HC Wainwright & Co. Buy → Buy $85
2025-01-23 init Piper Sandler — → Overweight $93
2025-01-10 init Cantor Fitzgerald — → Overweight —
2025-01-10 init HC Wainwright & Co. — → Buy $85
2024-11-25 init Baird — → Outperform $75
News
RSS: Latest DRUG news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-24 Fryzuk (Jeremy) Director of Issuer — 10,000 $1.34 $13,430
2026-02-24 Fryzuk (Jeremy) Director of Issuer — 7,500 $1.20 $9,030
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
13.94
+393.76%
2.82
-61.78%
7.39
-50.68%
14.98
Research And Development
11.08
+839.36%
1.18
-76.40%
5.00
-58.95%
12.18
Selling General And Administration
2.57
+77.47%
1.45
-34.29%
2.20
-13.77%
2.55
Selling And Marketing Expense
0.43
+932.83%
0.04
-65.16%
0.12
-78.36%
0.55
General And Administrative Expense
2.14
+52.12%
1.40
-32.51%
2.08
+4.06%
2.00
Salaries And Wages
0.50
+0.71%
0.49
-57.30%
1.16
+1063.06%
0.10
Other Gand A
1.64
+80.02%
0.91
-1.48%
0.92
-51.37%
1.90
Other Operating Expenses
0.29
+45.88%
0.20
+5.64%
0.19
-23.21%
0.24
Total Expenses
13.94
+393.76%
2.82
-61.78%
7.39
-50.68%
14.98
Operating Income
-13.94
-393.76%
-2.82
+61.78%
-7.39
+50.68%
-14.98
EBITDA
-13.86
-404.13%
-2.75
+62.41%
-7.31
+51.14%
-14.97
Normalized EBITDA
-14.05
-412.74%
-2.74
+62.61%
-7.33
+51.08%
-14.98
Reconciled Depreciation
0.08
+4.79%
0.07
+1.25%
0.07
+1100.10%
0.01
EBIT
-13.94
-393.76%
-2.82
+61.78%
-7.39
+50.68%
-14.98
Total Unusual Items
0.19
+2127.15%
-0.01
-165.63%
0.01
+39.78%
0.01
Total Unusual Items Excluding Goodwill
0.19
+2127.15%
-0.01
-165.63%
0.01
+39.78%
0.01
Special Income Charges
—
0.00
0.00
+100.00%
-0.00
Impairment Of Capital Assets
—
0.00
0.00
-100.00%
0.00
Net Income
-12.23
-336.46%
-2.80
+61.99%
-7.37
+50.74%
-14.96
Pretax Income
-12.23
-336.46%
-2.80
+61.99%
-7.37
+50.74%
-14.96
Net Non Operating Interest Income Expense
1.52
+4942.54%
0.03
0.00
0.00
Net Interest Income
1.52
+4942.54%
0.03
0.00
0.00
Interest Income Non Operating
1.52
+4942.54%
0.03
0.00
0.00
Interest Income
1.52
+4942.54%
0.03
0.00
0.00
Other Income Expense
0.19
+2127.15%
-0.01
-165.63%
0.01
+39.78%
0.01
Other Non Operating Income Expenses
—
—
—
-0.24
Gain On Sale Of Security
0.19
+2127.15%
-0.01
-165.63%
0.01
+16.77%
0.01
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-12.23
-336.46%
-2.80
+61.99%
-7.37
+50.74%
-14.96
Net Income From Continuing Operation Net Minority Interest
-12.23
-336.46%
-2.80
+61.99%
-7.37
+50.74%
-14.96
Net Income From Continuing And Discontinued Operation
-12.23
-336.46%
-2.80
+61.99%
-7.37
+50.74%
-14.96
Net Income Continuous Operations
-12.23
-336.46%
-2.80
+61.99%
-7.37
+50.74%
-14.96
Normalized Income
-12.42
-344.67%
-2.79
+62.19%
-7.39
+50.68%
-14.98
Net Income Common Stockholders
-12.23
-336.46%
-2.80
+61.99%
-7.37
+50.74%
-14.96
Diluted EPS
-1.78
-173.85%
-0.65
+67.17%
-1.98
+67.33%
-6.06
Basic EPS
-1.78
-173.85%
-0.65
+67.17%
-1.98
+67.33%
-6.06
Basic Average Shares
6.88
+59.58%
4.31
+15.87%
3.72
+50.57%
2.47
Diluted Average Shares
6.88
+59.58%
4.31
+15.87%
3.72
+50.57%
2.47
Diluted NI Availto Com Stockholders
-12.23
-336.46%
-2.80
+61.99%
-7.37
+50.74%
-14.96
Total Other Finance Cost
—
—
—
—
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Assets
84.42
+1282.92%
6.10
-11.26%
6.88
-43.09%
12.09
Current Assets
84.31
+1308.22%
5.99
-12.12%
6.81
-42.98%
11.95
Cash Cash Equivalents And Short Term Investments
82.91
+1349.43%
5.72
-15.23%
6.75
-41.97%
11.63
Cash And Cash Equivalents
82.91
+1349.43%
5.72
-15.23%
6.75
-41.97%
11.63
Cash Equivalents
0.09
+0.00%
0.09
+0.00%
0.09
+0.00%
0.09
Cash Financial
82.82
+1370.09%
5.63
-15.43%
6.66
-42.28%
11.54
Receivables
0.41
+722.46%
0.05
+35.81%
0.04
-76.26%
0.16
Other Receivables
—
—
—
0.04
Taxes Receivable
0.21
+317.96%
0.05
+35.81%
0.04
-67.71%
0.11
Accrued Interest Receivable
0.20
0.00
—
—
Prepaid Assets
0.99
+356.04%
0.22
+682.28%
0.03
-83.16%
0.16
Total Non Current Assets
0.11
-4.84%
0.12
+77.16%
0.07
-52.17%
0.14
Net PPE
0.11
-4.84%
0.12
+77.16%
0.07
-52.17%
0.14
Gross PPE
0.11
-4.84%
0.12
+77.16%
0.07
-52.17%
0.14
Properties
0.00
0.00
0.00
0.00
Other Properties
—
—
—
0.14
Leases
0.11
-4.84%
0.12
+77.16%
0.07
-52.17%
0.14
Goodwill And Other Intangible Assets
—
—
—
0.00
Total Liabilities Net Minority Interest
2.38
+318.23%
0.57
+102.33%
0.28
-81.82%
1.54
Current Liabilities
2.34
+341.73%
0.53
+88.24%
0.28
-80.93%
1.47
Payables And Accrued Expenses
2.25
+400.97%
0.45
+116.73%
0.21
-85.24%
1.40
Payables
1.71
+319.65%
0.41
+123.55%
0.18
-85.37%
1.25
Accounts Payable
1.71
+319.65%
0.41
+123.55%
0.18
-85.37%
1.25
Current Accrued Expenses
0.54
+1194.70%
0.04
+67.00%
0.03
-84.19%
0.16
Current Debt And Capital Lease Obligation
0.08
+6.48%
0.08
+7.93%
0.07
+8.27%
0.07
Current Capital Lease Obligation
0.08
+6.48%
0.08
+7.93%
0.07
+8.27%
0.07
Total Non Current Liabilities Net Minority Interest
0.04
+4.23%
0.04
0.00
-100.00%
0.07
Long Term Debt And Capital Lease Obligation
0.04
+4.23%
0.04
0.00
-100.00%
0.07
Long Term Capital Lease Obligation
0.04
+4.23%
0.04
0.00
-100.00%
0.07
Stockholders Equity
82.04
+1381.93%
5.54
-16.09%
6.60
-37.41%
10.54
Common Stock Equity
82.04
+1381.93%
5.54
-16.09%
6.60
-37.41%
10.54
Capital Stock
123.25
+247.93%
35.42
+4.45%
33.91
+5.20%
32.24
Common Stock
123.25
+247.93%
35.42
+4.45%
33.91
+5.20%
32.24
Share Issued
7.64
+68.78%
4.52
+19.94%
3.77
+7.21%
3.52
Ordinary Shares Number
7.64
+68.78%
4.52
+19.94%
3.77
+7.21%
3.52
Retained Earnings
-46.58
-35.60%
-34.35
-8.88%
-31.55
-30.50%
-24.17
Gains Losses Not Affecting Retained Earnings
5.37
+34.12%
4.01
+17.87%
3.40
+37.09%
2.48
Total Equity Gross Minority Interest
82.04
+1381.93%
5.54
-16.09%
6.60
-37.41%
10.54
Total Capitalization
82.04
+1381.93%
5.54
-16.09%
6.60
-37.41%
10.54
Working Capital
81.97
+1401.84%
5.46
-16.44%
6.53
-37.65%
10.48
Invested Capital
82.04
+1381.93%
5.54
-16.09%
6.60
-37.41%
10.54
Total Debt
0.13
+5.73%
0.12
+61.74%
0.07
-47.43%
0.14
Capital Lease Obligations
0.13
+5.73%
0.12
+61.74%
0.07
-47.43%
0.14
Net Tangible Assets
82.04
+1381.93%
5.54
-16.09%
6.60
-37.41%
10.54
Tangible Book Value
82.04
+1381.93%
5.54
-16.09%
6.60
-37.41%
10.54
Other Equity Interest
—
0.46
-45.23%
0.83
—
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Operating Cash Flow
-8.69
-369.77%
-1.85
+73.66%
-7.02
+48.30%
-13.59
Cash Flow From Continuing Operating Activities
-8.69
-369.77%
-1.85
+73.66%
-7.02
+48.30%
-13.59
Net Income From Continuing Operations
-12.23
-336.46%
-2.80
+61.99%
-7.37
+50.74%
-14.96
Depreciation Amortization Depletion
0.08
+4.79%
0.07
+1.25%
0.07
+1100.10%
0.01
Depreciation
0.08
+4.79%
0.07
+1.25%
0.07
+1100.10%
0.01
Depreciation And Amortization
0.08
+4.79%
0.07
+1.25%
0.07
+1100.10%
0.01
Other Non Cash Items
0.04
+300.79%
0.01
-54.71%
0.02
-32.88%
0.03
Stock Based Compensation
3.18
+279.00%
0.84
-27.11%
1.15
+31.66%
0.88
Asset Impairment Charge
—
0.00
0.00
-100.00%
0.00
Operating Gains Losses
-0.31
-2987.96%
-0.01
-122.33%
0.05
+117.52%
-0.26
Net Foreign Currency Exchange Gain Loss
-0.31
-2987.96%
-0.01
-122.33%
0.05
+117.52%
-0.26
Change In Working Capital
0.55
+1294.00%
0.04
+104.23%
-0.94
-230.05%
0.72
Change In Receivables
-0.36
-2639.92%
-0.01
-111.15%
0.12
+360.33%
-0.05
Change In Prepaid Assets
-0.77
-308.22%
-0.19
-238.17%
0.14
+3519.30%
0.00
Change In Payables And Accrued Expense
1.69
+598.01%
0.24
+120.21%
-1.20
-256.30%
0.77
Change In Other Current Liabilities
—
—
—
0.00
Financing Cash Flow
85.57
+10456.43%
0.81
-62.98%
2.19
-57.86%
5.20
Cash Flow From Continuing Financing Activities
85.57
+10456.43%
0.81
-62.98%
2.19
-57.86%
5.20
Net Issuance Payments Of Debt
-0.10
-11.61%
-0.09
-4.20%
-0.09
-1102.35%
-0.01
Repayment Of Debt
-0.10
-11.61%
-0.09
-4.20%
-0.09
-1102.35%
-0.01
Long Term Debt Payments
-0.10
-11.61%
-0.09
-4.20%
-0.09
-1102.35%
-0.01
Net Long Term Debt Issuance
-0.10
-11.61%
-0.09
-4.20%
-0.09
-1102.35%
-0.01
Net Common Stock Issuance
82.10
+9021.95%
0.90
-26.08%
1.22
-69.83%
4.03
Proceeds From Stock Option Exercised
3.93
+1301295.70%
0.00
-99.97%
1.09
-44.87%
1.97
Net Other Financing Charges
-0.36
—
-0.03
+96.63%
-0.80
Changes In Cash
76.88
+7494.66%
-1.04
+78.50%
-4.83
+42.38%
-8.39
Effect Of Exchange Rate Changes
0.31
+2567.45%
0.01
+125.84%
-0.05
-117.52%
0.26
Beginning Cash Position
5.72
-15.23%
6.75
-41.97%
11.63
-41.15%
19.76
End Cash Position
82.91
+1349.43%
5.72
-15.23%
6.75
-41.97%
11.63
Free Cash Flow
-8.69
-369.77%
-1.85
+73.66%
-7.02
+48.30%
-13.59
Common Stock Issuance
82.10
+9021.95%
0.90
-26.08%
1.22
-69.83%
4.03
Issuance Of Capital Stock
82.10
+9021.95%
0.90
-26.08%
1.22
-69.83%
4.03
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category